Accelerated solvent extraction of alkylresorcinols in food products containing uncooked and cooked wheat.

This research focuses on the overall extraction process of alkylresorcinols (ARs) from uncooked grains and baked products that have been processed with wheat, corn, rice, and white flour. Previously established extraction methods developed by Ross and colleagues, as well as a semiautomated method involving accelerated solvent extraction (ASE), were applied to extract ARs within freshly ground samples. For extraction of alkylresorcinols, nonpolar solvents such as ethyl acetate have been recommended for the extraction of uncooked foods, and polar solvents such as 1-propanol:water (3:1 v/v) have been recommended for the extraction of baked foods that contain rye, wheat, or other starch-rich grains. A comparison of AR extraction methods has been investigated with the application of gas chromatography and a flame ionization detector (GC-FID) to quantify the AR content. The goal of this research was to compare the rapid accelerated solvent extraction of the alkylresorcinols (ASE-AR) method to the previous manual AR extraction methods. Results for this study as well as the investigation of the overall efficiency of ASE-AR extraction with the use of a spiking study indicated that it can be comparable to current extraction methods but with less time required. Furthermore, the extraction time for ASE (approximately 40 min) is much more convenient and less tedious and time-consuming than previously established methods, which range from 5 h for processed foods to 24 h for raw grains.

Anthelmintic screening of Sub-Saharan African plants used in traditional medicine.

AIM OF STUDY: This study screened for anthelmintic activity of plant species traditionally used in the treatment of intestinal parasites and their symptoms in Sub-Saharan Africa in an effort to confirm their local use and aid in the search for new compounds since resistance is a growing concern. MATERIALS AND METHODS: Aqueous and organic extracts of 33 plant parts from 17 plant species traditionally used in the treatment of intestinal infections in Sub-Saharan Africa were evaluated for their anthelmintic activity. This activity was assessed using a standard motility assay against a levamisole resistant strain of the nematode Caenorhabditis elegans. RESULTS AND CONCLUSIONS: Anthelmintic activity was confirmed in 12 plant species. Of these, eight showed strong evidence of activity (p<0.0001), one exhibited moderate evidence of activity (p<0.001), three demonstrated weak evidence of activity (p<0.05), and five plants showed no evidence of activity. The eight species with the strongest evidence of activity were Acacia polyacantha, Anogeissus leiocarpus, Bridelia micrantha, Cassia sieberiana, Combretum nigricans, Grewia bicolor, Strychnos spinosa and Ziziphus mucronata. In only two cases, Anogeissus leiocarpus and Cassia sieberiana, anthelmintic activity has been previously confirmed. The activity demonstrated against the levamisole resistant strain of Caenorhabditis elegans and the presence of molecules in these plants known or suspected of having a broad spectrum of activity provide support for further study of these plants and their compounds as possible treatments for parasitic worm infections.

Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial.

CONTEXT: Herbal extracts from Commiphora mukul (guggul) have been widely used in Asia as cholesterol-lowering agents, and their popularity is increasing in the United States. Recently, guggulsterones, the purported bioactive compounds of guggul, have been shown to be potent antagonists of 2 nuclear hormone receptors involved in cholesterol metabolism, establishing a plausible mechanism of action for the hypolipidemic effects of these extracts. However, there are currently no published safety or efficacy data on the use of guggul extracts in Western populations. OBJECTIVE: To study the short-term safety and efficacy of 2 doses of a standardized guggul extract (guggulipid, containing 2.5% guggulsterones) in healthy adults with hyperlipidemia eating a typical Western diet. DESIGN: Double-blind, randomized, placebo-controlled trial using a parallel design, conducted March 2000-August 2001. PARTICIPANTS AND SETTING: A total of 103 ambulatory, community-dwelling, healthy adults with hypercholesterolemia in the Philadelphia, Pa, metropolitan area. INTERVENTION: Oral, 3 times daily doses of standard-dose guggulipid (1000 mg), high-dose guggulipid (2000 mg), or matching placebo. MAIN OUTCOME MEASURES: Percentage change in levels of directly measured low-density lipoprotein cholesterol (LDL-C) after 8 weeks of therapy. Secondary outcome measures included levels of total cholesterol, high-density lipoprotein cholesterol (HDL-C), triglycerides, and directly measured very low-density lipoprotein cholesterol (VLDL-C), as well as adverse events reports and laboratory safety measures including electrolyte levels and hepatic and renal function. RESULTS: Compared with participants randomized to placebo (n = 36), in whom levels of LDL-C decreased by 5%, both standard-dose guggulipid (n = 33) and high-dose guggulipid (n = 34) raised levels of LDL-C by 4% (P =.01 vs placebo) and 5% (P =.006 vs placebo), respectively, at 8 weeks, for a net positive change of 9% to 10%. There were no significant changes in levels of total cholesterol, HDL-C, triglycerides, or VLDL-C in response to treatment with guggulipid in the intention-to-treat analysis. While guggulipid was generally well tolerated, 6 participants treated with guggulipid developed a hypersensitivity rash compared with none in the placebo group. CONCLUSIONS: Despite plausible mechanisms of action, guggulipid did not appear to improve levels of serum cholesterol over the short term in this population of adults with hypercholesterolemia, and might in fact raise levels of LDL-C. Guggulipid also appeared to cause a dermatologic hypersensitivity reaction in some patients.